Coya Therapeutics, Inc. (COYA) Earnings
Coya Therapeutics, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 11, 2026
From the latest earnings 8-K
Revenue • FY2025
$7.95M
▲ 123.6%YoY
Diluted EPS • FY2025
$-1.27
▼ 29.6%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from COYA's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $7.95M | -$21.23M | — | $-1.27 | — | -283.9% | +123.6% |
| FY2024 | $3.55M | -$14.88M | — | $-0.98 | — | -485.4% | -40.8% |
| FY2023 | $6M | -$7.99M | — | $-0.79 | — | -131.7% | — |
| FY2022 | $0 | -$12.24M | — | $-4.73 | — | — | — |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 11, 2026 | 8-K (2.02) | 0001193125-26-343473EDGAR |
| May 12, 2026 | 8-K (2.02) | 0001193125-26-218198EDGAR |
| Mar 16, 2026 | 8-K (2.02) | 0001193125-26-107276EDGAR |
| Nov 12, 2025 | 8-K (2.02) | 0001193125-25-276022EDGAR |
| Aug 12, 2025 | 8-K (2.02) | 0000950170-25-106932EDGAR |
| May 13, 2025 | 8-K (2.02) | 0000950170-25-069819EDGAR |
| Mar 18, 2025 | 8-K (2.02) | 0000950170-25-040779EDGAR |
| Nov 6, 2024 | 8-K (2.02) | 0000950170-24-121833EDGAR |
Never miss a COYA filing.
Get an email when COYA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 17, 2026Source: SEC EDGAR.